<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810509</url>
  </required_header>
  <id_info>
    <org_study_id>Warfarin TTR-01</org_study_id>
    <nct_id>NCT02810509</nct_id>
  </id_info>
  <brief_title>Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea</brief_title>
  <official_title>Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study aims to assess the quality of anticoagulation with warfarin in real world
      practice of secondary stroke prevention in Korean patients with Atrial fibrillation (AF) and
      to explore predictors for poor International Normalized Range (INR) control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To assess the quality of anticoagulation with warfarin in real world practice of Korea
           for secondary stroke prevention in patients with AF-related Cardioembolic (CE) stroke 1)
           who initiated warfarin therapy and treatment at least for more than 7 days of warfarin
           adjustment period (warfarin-initiated cohort), and 2) who initiated and maintained
           warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment
           period (long-term warfarin-treated cohort).

        -  To explore predictors for poor INR control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time in TTR, the Percentage of Time in the Therapeutic Range of INR Between 2.0-3.0.</measure>
    <time_frame>We will analyze INR data of patients who had AF-related ischemic stroke and were treated with warfarin therapy at least for more than 7 days of warfarin adjustment period. (The INR follow up duration: 1 ~ maximum 3 years)</time_frame>
    <description>The primary outcome is TTR as measured by the percentage of time in the therapeutic range of INR between 2.0-3.0, using the Rosendaal linear interpolation method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of INR Values in the Therapeutic Range of 2.0-3.0: Numbers of INR Values Within the Therapeutic Range by the Total Numbers of INR Measured.</measure>
    <time_frame>We will analyze INR data of patients who had AF-related ischemic stroke and were treated with warfarin therapy at least for more than 7 days of warfarin adjustment period. (The INR follow up duration: 1 ~ maximum 3 years)</time_frame>
    <description>The secondary outcome is the percentage of INR values in the therapeutic range of 2.0-3.0: numbers of INR values within the therapeutic range divided by the total numbers of INR measured.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1814</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Short-term Warfarin-treated cohort</arm_group_label>
    <description>admission due to AF-related ischemic stroke (known AF or newly detected AF)
for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
TTR evaluable days &lt; 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long-term Warfarin-treated cohort</arm_group_label>
    <description>admission due to AF-related ischemic stroke (known AF or newly detected AF)
long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period
for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
TTR evaluable days ≥ 90 days</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients who admitted to 16 participating centers due to AF-related ischemic
        stroke between Jan 1, 2011 and Dec 31, 2012 and started warfarin therapy for secondary
        stroke prevention will be enrolled in this study. The number of patients is expected to be
        2,217 for the warfarin-initiated cohort and 1,057 for the long-term warfarin-treated
        cohort.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria for the warfarin-initiated cohort

          1. Admission due to AF-related ischemic stroke

          2. Initiation of warfarin therapy and treatment at least for more than 7 days of warfarin
             adjustment period

          3. For TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin
             adjustment

        Inclusion criteria for the long-term warfarin-treated cohort

          1. Admission due to AF-related ischemic stroke

          2. Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin
             adjustment period

          3. For TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin
             adjustment

          4. TTR evaluable days ≥ 90 days

        Exclusion Criteria:

          1. AF with mechanical valve

          2. Enrollment in anticoagulation randomized clinical trial

          3. Enrollment in studies affecting the target INR range.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keun-Sik Hong, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Ilsan Paik Hospital Inje University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hallym University College of Medicine</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University College of Medicine</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University School of Medicine</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Medical School</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ilsan Paik Hospital Inje University</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital, Jeju National University College of Medicine</name>
      <address>
        <city>Jeju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji General Hospital, Eulji University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <results_first_submitted>January 25, 2017</results_first_submitted>
  <results_first_submitted_qc>August 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2019</results_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inje University</investigator_affiliation>
    <investigator_full_name>Keun-Sik Hong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Wafarin</keyword>
  <keyword>Cardioembolic (CE) stroke</keyword>
  <keyword>ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Short Term Wafarin-treated Cohort</title>
          <description>admission due to AF-related ischemic stroke (known AF or newly detected AF)
for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
TTR evaluable days &lt; 90 days</description>
        </group>
        <group group_id="P2">
          <title>Long Term Warfarin-treated Cohort</title>
          <description>admission due to AF-related ischemic stroke (known AF or newly detected AF)
long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period
for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
TTR evaluable days ≥ 90 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="584"/>
                <participants group_id="P2" count="1230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="584"/>
                <participants group_id="P2" count="1230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Overall number of Baseline participants are divided by short term and Long term Warfarin-treated cohort.</population>
      <group_list>
        <group group_id="B1">
          <title>Short Term Wafarin-treated Cohort</title>
          <description>Admission due to AF-related ischemic stroke (known AF or newly detected AF)
for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
TTR evaluable days &lt; 90 days</description>
        </group>
        <group group_id="B2">
          <title>Long Term Warfarin-treated Cohort</title>
          <description>Admission due to AF-related ischemic stroke
Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period
For Time in TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment
TTR evaluable days ≥ 90 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="584"/>
            <count group_id="B2" value="1230"/>
            <count group_id="B3" value="1814"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.71" spread="9.60"/>
                    <measurement group_id="B2" value="70.08" spread="9.73"/>
                    <measurement group_id="B3" value="71.25" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="523"/>
                    <measurement group_id="B3" value="821"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="286"/>
                    <measurement group_id="B2" value="707"/>
                    <measurement group_id="B3" value="993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time in TTR, the Percentage of Time in the Therapeutic Range of INR Between 2.0-3.0.</title>
        <description>The primary outcome is TTR as measured by the percentage of time in the therapeutic range of INR between 2.0-3.0, using the Rosendaal linear interpolation method.</description>
        <time_frame>We will analyze INR data of patients who had AF-related ischemic stroke and were treated with warfarin therapy at least for more than 7 days of warfarin adjustment period. (The INR follow up duration: 1 ~ maximum 3 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Short-term Cohort</title>
            <description>admission due to AF-related ischemic stroke (known AF or newly detected AF)
for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
TTR evaluable days &lt; 90 days</description>
          </group>
          <group group_id="O2">
            <title>Long-term Cohort</title>
            <description>admission due to AF-related ischemic stroke (known AF or newly detected AF)
long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period
for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
TTR evaluable days ≥ 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time in TTR, the Percentage of Time in the Therapeutic Range of INR Between 2.0-3.0.</title>
          <description>The primary outcome is TTR as measured by the percentage of time in the therapeutic range of INR between 2.0-3.0, using the Rosendaal linear interpolation method.</description>
          <units>percentage of time in therapeutic range</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="584"/>
                <count group_id="O2" value="1230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" spread="26.3"/>
                    <measurement group_id="O2" value="49.1" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of INR Values in the Therapeutic Range of 2.0-3.0: Numbers of INR Values Within the Therapeutic Range by the Total Numbers of INR Measured.</title>
        <description>The secondary outcome is the percentage of INR values in the therapeutic range of 2.0-3.0: numbers of INR values within the therapeutic range divided by the total numbers of INR measured.</description>
        <time_frame>We will analyze INR data of patients who had AF-related ischemic stroke and were treated with warfarin therapy at least for more than 7 days of warfarin adjustment period. (The INR follow up duration: 1 ~ maximum 3 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Short-term Cohort</title>
            <description>Admission due to AF-related ischemic stroke (known AF or newly detected AF)
for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
TTR evaluable days &lt; 90 days</description>
          </group>
          <group group_id="O2">
            <title>Long-term Cohort</title>
            <description>Admission due to AF-related ischemic stroke
Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period
For Time in TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment
TTR evaluable days ≥ 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of INR Values in the Therapeutic Range of 2.0-3.0: Numbers of INR Values Within the Therapeutic Range by the Total Numbers of INR Measured.</title>
          <description>The secondary outcome is the percentage of INR values in the therapeutic range of 2.0-3.0: numbers of INR values within the therapeutic range divided by the total numbers of INR measured.</description>
          <units>Number of INR measured</units>
          <param>Count of Units</param>
          <units_analyzed>Number of INR measured</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="584"/>
                <count group_id="O2" value="1230"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of INR measured</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8693"/>
                <count group_id="O2" value="33941"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3900"/>
                    <measurement group_id="O2" value="15120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This is an investigator-initiated study of a retrospective observation study therefore, adverse events and serious adverse events are not collected through this study.</time_frame>
      <desc>This is an investigator-initiated study of a retrospective observation study therefore, adverse events and serious adverse events are not collected through this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Warfarin-initiated Cohort</title>
          <description>Admission due to AF-related ischemic stroke
Initiation of warfarin therapy and treatment at least for more than 7 days of warfarin adjustment period
For Time in therapeutic range (TTR) calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment</description>
        </group>
        <group group_id="E2">
          <title>Long Term Warfarin-treated Cohort</title>
          <description>Admission due to AF-related ischemic stroke
Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period
For Time in TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment
TTR evaluable days ≥ 90 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Keun-Sik Hong, MD, PhD, Prof</name_or_title>
      <organization>Ilsan Paik Hospital Inje University</organization>
      <phone>82-31-910-7680</phone>
      <email>nrhks@paik.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

